Anandamide, acting via CB2 receptors, alleviates LPS-induced neuroinflammation in rat primary microglial cultures

Neural Plasticity

Volumn 2015, Issue , 2015, Pages

  Malek, Natalia ^a   Popiolek Barczyk, Katarzyna ^a   Mika, Joanna ^a   Przewlocka, Barbara ^a   Starowicz, Katarzyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID 2 RECEPTOR; CID 16020046; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; NITRIC OXIDE; UNCLASSIFIED DRUG; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; CNR2 PROTEIN, RAT; GPR18 PROTEIN, RAT; GPR55 PROTEIN, RAT; IMMUNOLOGIC FACTOR; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; MICROGLIAL CELL CULTURE; NERVOUS SYSTEM INFLAMMATION; NEWBORN; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; ENCEPHALITIS; METABOLISM; MICROGLIA; WISTAR RAT;

ANIMALS; ARACHIDONIC ACIDS; CELLS, CULTURED; ENCEPHALITIS; ENDOCANNABINOIDS; IMMUNOLOGIC FACTORS; LIPOPOLYSACCHARIDES; MICROGLIA; NITRIC OXIDE; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84930673599     PISSN: 20905904     EISSN: 16875443     Source Type: Journal    
DOI: 10.1155/2015/130639     Document Type: Article

References (64)

1. M. Song, J. Jin, J.-E. Lim et al., "TLR4 mutation reduces microglial activation, increases A deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease," Journal of Neuroinflammation, vol. 8, article 92, 2011.
2. C. M. R. Barcia, "IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease," Cell Death & Disease, vol. 2, p. e142, 2011.
3. S. H. Appel, W. Zhao, D. R. Beers, and J. S. Henkel, "The microglial-motoneuron dialogue in ALS," Acta Myologica, vol. 30, no. 1, pp. 4-8, 2011.
4. A. Y. Lai and K. G. Todd, "Microglia in cerebral ischemia: molecular actions and interactions," Canadian Journal of Physiology and Pharmacology, vol. 84, no. 1, pp. 49-59, 2006.
5. J. Mika, M. Osikowicz, E. Rojewska et al., "Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain," European Journal of Pharmacology, vol. 623, no. 1-3, pp. 65-72, 2009.
6. M. L. Loggia,D. B.Chonde, O. Akeju et al., "Evidence for brain glial activation in chronic pain patients," Brain, vol. 138, part 3, pp. 604-615, 2015.
7. A. O. Caggiano, C. D. Breder, and R. P. Kraig, "Long-term elevation of cyclooxygenase-2, but not lipoxygenase, in regions synaptically distant from spreading depression," Journal of Comparative Neurology, vol. 376, no. 3, pp. 447-462, 1996.
8. C. J. Hauser, "Regional macrophage activation after injury and the compartmentalization of inflammation in trauma," New Horizons, vol. 4, no. 2, pp. 235-251, 1996.
9. J. E. Merrill and E. N. Benveniste, "Cytokines in inflammatory brain lesions: helpful and harmful," Trends inNeurosciences, vol. 19, no. 8, pp. 331-338, 1996.
10. C. Cunningham, "Microglia and neurodegeneration: the role of systemic inflammation," Glia, vol. 61, no. 1, pp. 71-90, 2013.
11. J. M. Crain, M. Nikodemova, and J. J. Watters, "Microglia express distinctM1 andM2phenotypic markers in the postnatal and adult central nervous system in male and female mice," Journal of Neuroscience Research, vol. 91, no. 9, pp. 1143-1151, 2013.
12. X. Hu, P. Li, Y. Guo et al., "Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia," Stroke, vol. 43, no. 11, pp. 3063-3070, 2012.
13. E. Rojewska, K. Popiolek-Barczyk, A. M. Jurga, W. Makuch, B. Przewlocka, and J. Mika, "Involvement of pro- and antinociceptive factors in minocycline analgesia in rat neuropathic pain model," Journal ofNeuroimmunology, vol. 277, no. 1-2,pp. 57-66, 2014.
14. W. Y. Tam and C. H. E. Ma, "Bipolar/rod-shaped microglia are proliferating microglia with distinct M1/M2 phenotypes," Scientific Reports, vol. 4, article 7279, 2014.
15. Y. Nishio, M. Koda, M. Hashimoto et al., "Deletion of macrophage migration inhibitory factor attenuates neuronal death and promotes functional recovery after compressioninduced spinal cord injury in mice," Acta Neuropathologica, vol. 117, no. 3, pp. 321-328, 2009.
16. P. G. Popovich, Z.Guan, P.Wei, I.Huitinga,N. van Rooijen, and B. T. Stokes, "Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury," Experimental Neurology, vol. 158, no. 2, pp. 351-365, 1999.
17. B. Koscsó, B. Csóka, E. Kókai et al., "Adenosine augments IL- 10-induced STAT3 signaling in M2c macrophages," Journal of Leukocyte Biology, vol. 94, no. 6, pp. 1309-1315, 2013.
18. S. Poole, F. Q. Cunha, S. Selkirk, B. B. Lorenzetti, and S. H. Ferreira, "Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10," British Journal of Pharmacology, vol. 115, no. 4, pp. 684-688, 1995.
19. Y. Marchalant, S. Rosi, and G. L. Wenk, "Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation," Neuroscience, vol. 144, no. 4, pp. 1516-1522, 2007.
20. M. Van der Stelt and V. Di Marzo, "Cannabinoid receptors and their role in neuroprotection," NeuroMolecular Medicine, vol. 7, no. 1-2, pp. 37-50, 2005.
21. C. Andradas, M. M. Caffarel, E. Pérez-Gómez et al., "The orphanGprotein-coupled receptorGPR55 promotes cancer cell proliferation via ERK," Oncogene, vol. 30, no. 2, pp. 245-252, 2011.
22. N. A. B. Balenga, C. M. Henstridge, J. Kargl, and M.Waldhoer, "Pharmacology, signaling and physiological relevance of the G protein-coupled receptor 55," Advances in Pharmacology, vol. 62, pp. 251-277, 2011.
23. A. G. Hohmann, R. L. Suplita, N. M. Bolton et al., "An endocannabinoid mechanism for stress-induced analgesia," Nature, vol. 435, no. 7045, pp. 1108-1112, 2005.
24. G. A. Cabral, K. N. Harmon, and S. J. Carlisle, "Cannabinoidmediated inhibition of inducible nitric oxide production by rat microglial cells: Evidence for cb1 receptor participation," Advances in Experimental Medicine and Biology, vol. 493, pp. 207-214, 2001.
25. D. Sinha, T. I. Bonner, N. R. Bhat, and L. A. Matsuda, "Expression of the CB1 cannabinoid receptor in macrophagelike cells from brain tissue: immunochemical characterization by fusion protein antibodies," Journal of Neuroimmunology, vol. 82, no. 1, pp. 13-21, 1998.
26. L. Walter, A. Franklin, A. Witting, T. Möller, and N. Stella, "Astrocytes in culture produce anandamide and other acylethanolamides," The Journal of Biological Chemistry, vol. 277, no. 23, pp. 20869-20876, 2002.
27. Y. Liu, W. Hao, M. Letiembre et al., "Suppression of microglial inflammatory activity by myelin phagocytosis: role of p47- PHOX-mediated generation of reactive oxygen species," The Journal of Neuroscience, vol. 26, no. 50, pp. 12904-12913, 2006.
28. D. Baker, G. Pryce, J. L. Croxford et al., "Endocannabinoids control spasticity in a multiple sclerosis model," The FASEB Journal, vol. 15, no. 2, pp. 300-302, 2001.
29. C. Berger, P. C. Schmid, W.-R. Schabitz, M. Wolf, S. Schwab, and H. H. O. Schmidt, "Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?," Journal of Neurochemistry, vol. 88, no. 5, pp. 1159-1167, 2004.
30. B. G. Ramírez, C. Blázquez, T. Gómez Del Pulgar, M. Guzmán, and M. L. De Ceballos, "Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation," Journal of Neuroscience, vol. 25, no. 8, pp. 1904-1913, 2005.
31. M. Zawadzka and B. Kaminska, "A novelmechanism of FK506- mediated neuroprotection:Downregulation of cytokine expression in glial cells," Glia, vol. 49, no. 1, pp. 36-51, 2005.
32. K. Popiolek-Barczyk, E. Rojewska, A. M. Jurga et al., "Minocycline enhances the effectiveness of nociceptin/orphanin FQ during neuropathic pain," BioMed Research International, vol. 2014, Article ID762930, 12 pages, 2014.
33. P. Chomczynski and N. Sacchi, "Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction," Analytical Biochemistry, vol. 162, no. 1, pp. 156-159, 1987.
34. M. Schwartz, O. Butovsky, and J. Kipnis, "Does inflammation in an autoimmune disease differ from inflammation in neurodegenerative diseases?, Possible implications for therapy," Journal of Neuroimmune Pharmacology, vol. 1, no. 1, pp. 4-10, 2006.
35. J. Gehrmann, Y.Matsumoto, and G.W. Kreutzberg, "Microglia: intrinsic immuneffector cell of the brain," Brain Research Reviews, vol. 20, no. 3, pp. 269-287, 1995.
36. M. Zawadzka, M. Dabrowski, A. Gozdz et al., "Early steps of microglial activation are directly affected by neuroprotectant FK506 inboth invitroinflammationand in ratmodel of stroke," Journal of Molecular Medicine, vol. 90, no. 12, pp. 1459-1471, 2012.
37. G.Marsicano, S. Goodenough, K.Monory et al., "CB1 cannabinoid receptors and on-demand defense against excitotoxicity," Science, vol. 302, no. 5642, pp. 84-88, 2003.
38. E. Eljaschewitsch, A. Witting, C. Mawrin et al., "The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells," Neuron, vol. 49, no. 1, pp. 67-79, 2006.
39. G. A. Cabral and F. Marciano-Cabral, "Cannabinoid receptors in microglia of the central nervous system: immune functional relevance," Journal of Leukocyte Biology, vol. 78, no. 6, pp. 1192-1197, 2005.
40. M.Karsak, E. Gaffal, R. Date et al., "Attenuation of allergic contact dermatitis through the endocannabinoid system," Science, vol. 316, no. 5830, pp. 1494-1497, 2007.
41. J. Palazuelos, T. Aguado, M. R. Pazos et al., "Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity," Brain, vol. 132, part 11, pp. 3152-3164, 2009.
42. A. Romero-Sandoval, N. Nutile-Mcmenemy, and J. A. DeLeo, "Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury," Anesthesiology, vol. 108, no. 4, pp. 722-734, 2008.
43. L. Luongo, E. Palazzo, S. Tambaro et al., "1-(2,4-dichlorophenyl)- 6-methyl-N-cyclohexylamine-1,4-dihy droindeno [1,2]- c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice," Neurobiology of Disease, vol. 37, no. 1, pp. 177-185, 2010.
44. I. Racz, X. Nadal, J. Alferink et al., "Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain," Journal of Neuroscience, vol. 28, no. 46, pp. 12125-12135, 2008.
45. S. J. Carlisle, F. Marciano-Cabral, A. Staab, C. Ludwick, and G. A. Cabral, "Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation," International Immunopharmacology, vol. 2, no. 1, pp. 69-82, 2002.
46. K. Maresz, E. J. Carrier, E. D. Ponomarev, C. J. Hillard, and B. N. Dittel, "Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli," Journal of Neurochemistry, vol. 95, no. 2, pp. 437-445, 2005.
47. J. Ehrhart, D. Obregon, T. Mori et al., "Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation," Journal of Neuroinflammation, vol. 2, article 29, 2005.
48. K. A. Kigerl, J. C. Gensel, D. P. Ankeny, J. K. Alexander, D. J. Donnelly, and P. G. Popovich, "Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injuredmouse spinal cord," The Journal of Neuroscience, vol. 29, no. 43, pp. 13435-13444, 2009.
49. R. Glass and M. Synowitz, "CNS macrophages and peripheral myeloid cells in brain tumours," Acta Neuropathologica, vol. 128, no. 3, pp. 347-362, 2014.
50. T.W. Klein, C. A.Newton,N.Nakachi, and H. Friedman, "Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection," The Journal of Immunology, vol. 164, no. 12, pp. 6461-6466, 2000.
51. S. Rivest, "Cannabinoids in microglia: a new trick for immune surveillance and neuroprotection," Neuron, vol. 49, no. 1, pp. 4-8, 2006.
52. M. Prinz and U.-K. Hanisch, "Murine microglial cells produce and respond to interleukin-18," Journal of Neurochemistry, vol. 72, no. 5, pp. 2215-2218, 1999.
53. D. McHugh, S. S. J. Hu, N. Rimmerman et al., "N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor," BMC Neuroscience, vol. 11, article no. 44, 2010.
54. S. Chuchawankul, M. Shima, N. E. Buckley, C. B. Hartmann, and K. L. McCoy, "Role of cannabinoid receptors in inhibiting macrophage costimulatory activity," International Immunopharmacology, vol. 4, no. 2, pp. 265-278, 2004.
55. O. Ullrich, K.Merker, J. Timm, and S. Tauber, "Immune control by endocannabinoids - new mechanisms of neuroprotection?," Journal of Neuroimmunology, vol. 184, no. 1-2, pp. 127-135, 2007.
56. S. A. Kanaan, S. Poole, N. E. Saadé, S. Jabbur, and B. Safieh-Garabedian, "Interleukin-10 reduces the endotoxin-induced hyperalgesia in mice," Journal of Neuroimmunology, vol. 86, no. 2, pp. 142-150, 1998.
57. L. Aloe, M. L. Rocco, P. Bianchi, and L. Manni, "Nerve growth factor: from the early discoveries to the potential clinical use," Journal of TranslationalMedicine, vol. 10, no. 1, article 239, 2012.
58. R. A. Puffenbarger, A. C. Boothe, and G. A. Cabral, "Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells," Glia, vol. 29, no. 1, pp. 58-69, 2000.
59. P. C. Staton, J. P. Hatcher, D. J. Walker et al., "The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain," Pain, vol. 139, no. 1, pp. 225-236, 2008.
60. M. Pietr, E. Kozela, R. Levy et al., "Differential changes in GPR55 during microglial cell activation," FEBS Letters, vol. 583, no. 12, pp. 2071-2076, 2009.
61. D. McHugh, "GPR18 in microglia: implications for the CNS and endocannabinoid system signalling," British Journal of Pharmacology, vol. 167, no. 8, pp. 1575-1582, 2012.
62. N. A. Balenga, E. Martínez-Pinilla, J. Kargl et al., "Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling," British Journal of Pharmacology, vol. 171, no. 23, pp. 5387-5406, 2014.
63. N. A. B. Balenga, E. Aflaki, J. Kargl et al., "GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils," Cell Research, vol. 21, no. 10, pp. 1452-1469, 2011.
64. E. Moreno, C. Andradas, M. Medrano et al., "Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling," Journal of Biological Chemistry, vol. 289, no. 32, pp. 21960-21972, 2014.